Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06881784 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

Study acronym: RASolve 301
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 153 → 158 locations Eligibility criteria expanded, about 13 words · Secondary endpoints: details revised at 4 of 11 entries Show 2 more changesShow less
    • Eligibility criteria expanded, about 13 words
    • Secondary endpoints: details revised at 4 of 11 entries
  2. Study sites: 152 to 153v34
  3. Site contacts updated at 1 of 152 sitesv33
  4. Site contacts updated at 1 of 152 sitesv32
  5. Study sites: 151 to 152v31
  6. Trial sites expanded: 143 → 151 locationsv30
  7. Primary endpoint(s) modified Enrollment increased: 420 → 590 participants · Trial sites expanded: 129 → 143 locations · Secondary endpoints revised (11)v29 Show 3 more changesShow less
    • Enrollment increased: 420 → 590 participants
    • Trial sites expanded: 129 → 143 locations
    • Secondary endpoints revised (11)

    See this version in full on ClinicalTrials.gov ↗

  8. Study sites: 121 to 129v28
  9. Study sites: 113 to 121v27
  10. Study sites: 105 to 113v26
  11. Study sites: 104 to 105v25
  12. Study sites: 101 to 104v24
  13. Study sites: 97 to 101v23
  14. Study sites: 89 to 97v22
  15. Study sites: 83 to 89v21
  16. Study sites: 75 to 83v20
  17. Study sites: 68 to 75v19
  18. Study sites: 62 to 68v18
  19. Study sites: 44 to 62v17
  20. Primary endpoints revised (2) Study sites: 38 to 44 · Eligibility criteria revised · Study title shortened, about 2 wordsv16 Show 3 more changesShow less
    • Study sites: 38 to 44
    • Eligibility criteria revised
    • Study title shortened, about 2 words

    See this version in full on ClinicalTrials.gov ↗

  21. Study sites: 30 to 38v15
  22. Study sites: 26 to 30v14
  23. Study sites: 22 to 26v13
  24. Study sites: 21 to 22v12
  25. Study sites: 17 to 21v11
  26. Study sites: 14 to 17v10
  27. Study sites: 8 to 14v9
  28. Study sites: 6 to 8v8
  29. Study sites: 5 to 6v7
  30. Study sites: 4 to 5 Start date changed from estimate of May 30, 2025 to May 6, 2025v6 Show 1 more changeShow less
    • Start date changed from estimate of May 30, 2025 to May 6, 2025
  31. Study sites: 3 to 4v5
  32. Study sites: 1 to 3v4
  33. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1v3 Show 1 more changeShow less
    • Study sites: 0 to 1
  34. Study title shortened, about 7 wordsv2 See this version in full on ClinicalTrials.gov ↗
  35. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.
Trial Details
NCT Number NCT06881784
Lead Sponsor Revolution Medicines, Inc.
Conditions NSCLC (Non-small Cell Lung Cancer), Non-Small Cell Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), NSCLC (Advanced Non-small Cell Lung Cancer)
Enrollment 590 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov